UPDATE: MHRA Class 4 Medicines Defect Information: Atnahs Pharma UK Limited, Naprosyn Tablets (all strengths), Naprosyn EC 250mg Gastro-Resistant Tablets, Naprosyn EC 500mg Gastro-Resistant Tablets

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an update, following the medicines defect notification shared on 23 February 2022, this has been updated to reflect an update to expiry dates and the product name.

The full notification can be accessed via the link below, the changes from what the MHRA issued on 23 February are as follows:

• Correction to product name so that it now reads 'Naprosyn EC 250mg Gastro-Resistant Tablets PL 43252/0006' (previously the 'EC' was missing)
• Updates have been made to the expiry dates for all batches of PL 43252/006
• The link to the Patient Information Leaflet for PL 43252/006 has also been updated

This notification can be accessed here.